{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:56:52Z","timestamp":1761512212845},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,3,20]],"date-time":"2006-03-20T00:00:00Z","timestamp":1142812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The primary objective in the treatment of acute pediatric idiopathic thrombocytopenic purpura (ITP) is to rapidly increase the platelet count.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We built a decision analytic model to evaluate the cost\u2010utility of four commonly used treatment strategies: intravenous immunoglobulin G (IVIG) 0.8 g\/kg, anti\u2010D 75 mcg\/kg, methylprednisolone (30 mg\/kg for 3 days), and prednisone (4 mg\/kg\/day for 4 days). In our baseline model, all children were hospitalized upon presentation, and discharged once the platelet count reached \u226520,000. We performed a literature search to estimate time to platelet count \u226520,000 for each strategy, as well as the probability of side effects. We obtained cost data and quality of life measures from institutional and published data sources.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Total cost of one\u2010time treatment for a 20 kg child was $786 with prednisone, $1,346 with methylprednisolone, $2,035 with anti\u2010D, and $2,492 with IVIG. The strategies of IVIG and methylprednisolone were less effective and more expensive than anti\u2010D and prednisone, respectively. Although anti\u2010D caused the most rapid rise in platelet counts, the incremental cost\u2010utility ratio (costs incurred by using anti\u2010D instead of prednisone divided by health benefit of using anti\u2010D instead of prednisone) was $7,616 per day of severe thrombocytopenia avoided, primarily due to the much higher medication cost of anti\u2010D. Utilizing an outpatient model, the cost difference between anti\u2010D and prednisone was even more striking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The clinical benefit of anti\u2010D is offset by a substantial cost increase. Although often overlooked in favor of newer agents, a brief course of high\u2010dose prednisone is an inexpensive and effective treatment for acute ITP. Pediatr Blood Cancer 2007;48:173\u2013180. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20830","type":"journal-article","created":{"date-parts":[[2006,3,20]],"date-time":"2006-03-20T19:16:44Z","timestamp":1142882204000},"page":"173-180","source":"Crossref","is-referenced-by-count":29,"title":["A cost\u2010utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)"],"prefix":"10.1002","volume":"48","author":[{"given":"Sarah H.","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Kim","family":"Ritchey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,3,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.71.3.251"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-815628"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.1.3.3"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80400-7"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92205-5"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.1998.tb01239.x","article-title":"Short\u2010course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP)","volume":"424","author":"Carcao MD","year":"1998","journal-title":"Acta Paediatr Suppl"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80654-1"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880019309029508"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)82024-4"},{"key":"e_1_2_5_11_2","first-page":"376","article-title":"A prospective, randomized trial of conventional, dose\u2010accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura","volume":"72","author":"Fujisawa K","year":"2000","journal-title":"Int J Hematol"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1996.tb14183.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200210000-00008"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880010252899370"},{"key":"e_1_2_5_15_2","first-page":"295","article-title":"A randomized and comparative study of intravenous immunoglobulin and megadose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura","volume":"45","author":"Erduran E","year":"2003","journal-title":"Turk J Pediatr"},{"key":"e_1_2_5_16_2","first-page":"299a","article-title":"High\u2010dose anti\u2010D immune globulin is as effective as IVIG in the treatment of newly diagnosed immune thrombocytopenic purpura (ITP) in children","volume":"102","author":"Tarantino MD","year":"2003","journal-title":"Blood"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70367-7"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02627.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/08880010290097161"},{"key":"e_1_2_5_20_2","first-page":"139","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond MF","year":"1997"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)07219-1"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540150055031"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199705000-00004"},{"key":"e_1_2_5_24_2","first-page":"9","article-title":"Safety profile of WinRho anti\u2010D","volume":"35","author":"Hong F","year":"1998","journal-title":"Semin Hematol"},{"key":"e_1_2_5_25_2","first-page":"23","article-title":"Efficacy, safety, and dose response of intravenous anti\u2010D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children","volume":"35","author":"Freiberg A","year":"1998","journal-title":"Semin Hematol"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199806000-00002"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200111000-00009"},{"key":"e_1_2_5_28_2","unstructured":"Drug Topics Red Book: Montvale NY. Medical Economics 2004."},{"key":"e_1_2_5_29_2","unstructured":"From the Centers for Medicare and Medicaid Services web site. Available at:http:\/\/cms.hhs.gov\/providers\/pufdownload\/default.asp. Accessed March 29 2005."},{"key":"e_1_2_5_30_2","unstructured":"From the U.S. Bureau of Labor Statistics web site. Available at:http:\/\/www.bls.gov\/data\/. Accessed March 29 2005."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X0002000310"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200003)63:3<156::AID-AJH9>3.0.CO;2-4"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20295"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200302000-00009"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-15257"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204392"},{"key":"e_1_2_5_37_2","first-page":"1068","article-title":"Isolated thrombocytopenia in children with acute lymphoblastic leukemia: A rare event in a Pediatric Oncology Group Study","volume":"84","author":"Dubansky AS","year":"1989","journal-title":"Pediatrics"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20830","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T16:45:14Z","timestamp":1699980314000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,20]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1002\/pbc.20830"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20830","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,20]]}}}